FDA to look at price comparisons in Rx advertising
Anticipating a day when price comparisons may be a key element in prescription drug advertising, the FDA plans to study how best to present price information in physician and direct-to-consumer (DTC) ads without implying that two drugs are interchangeable. The results of the studies could dictate how drugmakers market biosimilars in the U.S.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter